Study guide

5.1 Medical Evaluation, Toxicology Screening, and Infectious Disease Risks

National Certified Addiction Counselor NCAC

Track your progress as you read

Finished sections get a check mark.

1 Introduction to NCAC & Addiction Counseling

0.1 NCAC Exam Structure, Eligibility, and Scoring 0.2 The 12 Core Functions & TAP 21 Addiction Counseling Competencies 0.3 Study Strategy and Exam Navigation for Addiction Counselors

2 Chapter 1: Screening, Intake, and Initial Orientation

1.1 Screening Instruments, Risk Stratification, and SBIRT Protocols 1.2 The Intake Process: Clinical and Administrative Data Collection 1.3 Client Orientation, Rights, Informed Consent, and Program Expectations 1.4 Mandated, Court-Referred, and Justice-Involved Clients

3 Chapter 2: Initial Case Management and Referral Foundations

2.1 Stages of Change (Transtheoretical Model) and Initial Engagement 2.2 Referral Coordination, Community Resources, and Interdisciplinary Linkage 2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement

4 Chapter 3: Biopsychosocial Assessment & Diagnostic Foundations

3.1 Comprehensive Biopsychosocial Assessment & The Addiction Severity Index (ASI) 3.2 DSM-5-TR Substance Use Disorders: Criteria, Specifiers, and Neurobiology of Addiction 3.3 Behavioral and Process Addictions: Assessment and Clinical Features 3.4 Models and Theories of Addiction Etiology

5 Chapter 4: Co-Occurring Disorders & Risk Assessment

4.1 Co-Occurring Mental Health Disorders & Differential Diagnosis 4.2 Suicide Risk Assessment, Self-Harm, and Crisis Safety Planning 4.3 Trauma-Informed Assessment, PTSD, and Adverse Childhood Experiences (ACEs)

6 Chapter 5: Medical, Toxicology, and Special Population Considerations

5.1 Medical Evaluation, Toxicology Screening, and Infectious Disease Risks 5.2 Cultural, Developmental, and Special Population Assessment Adaptations 5.3 Psychopharmacology of the Major Drug Classes 5.4 Physiological Effects of Substance Use Across Body Systems

7 Chapter 6: The ASAM Criteria & Level of Care Placement

6.1 The ASAM Criteria: The Six Multidimensional Assessment Dimensions 6.2 ASAM Continuum of Care: Levels 0.5 Through 4.0 6.3 Placement Matching, Continued Service, Transfer, and Discharge Criteria

8 Chapter 7: Individualized Treatment Planning & Pharmacotherapy

7.1 Developing Measurable, Individualized Treatment Plans (SMART Objectives) 7.2 Medications for Addiction Treatment (MAT/MOUD) and Pharmacotherapies 7.3 Monitoring Clinical Progress, Plan Review, and Interdisciplinary Care

9 Chapter 8: Case Management, Relapse Prevention & Continuing Care

8.1 Case Management Models, Advocacy, and Resource Coordination 8.2 Relapse Dynamics, Warning Signs, and Relapse Prevention Models 8.3 Continuing Care, Recovery Capital, and Peer Support Systems 8.4 Clinical Documentation, Progress Notes, and the Golden Thread 8.5 Outcome Measurement, Program Evaluation, and Evidence-Based Practice

10 Chapter 9: Core Counseling Modalities & Individual Skills

9.1 Motivational Interviewing: Spirit, Principles, OARS, and Change Talk 9.2 Cognitive Behavioral Therapy (CBT) & REBT in Addiction Treatment 9.3 Additional Evidence-Based Approaches: SFBT, Contingency Management, and Mindfulness 9.4 Mutual-Help Programs, Twelve-Step Facilitation, and Recovery Support

11 Chapter 10: Group Dynamics & Family Systems

10.1 Group Counseling Dynamics, Types of Groups, and Yalom's Therapeutic Factors 10.2 Group Leadership Skills, Managing Challenging Behaviors, and Developmental Stages 10.3 Family Systems Theory, Roles, Codependency, and Family Interventions

12 Chapter 11: Crisis Intervention & Psychoeducation

11.1 Crisis Intervention Models, De-escalation Techniques, and Overdose Response 11.2 Psychoeducation, Health Literacy, and Client Self-Advocacy

13 Chapter 12: Legal Standards, Confidentiality & 42 CFR Part 2

12.1 Federal Confidentiality Regulations: 42 CFR Part 2 and HIPAA Integration 12.2 Duty to Warn / Protect (Tarasoff) and Mandated Reporting Laws 12.3 Legal Issues, Subpoenas, Court Mandates, and Clinical Record Retention 12.4 Confidentiality with Minors, Groups, Families, and Collaterals

14 Chapter 13: NAADAC Ethics, Cultural Humility & Supervision

13.1 The NAADAC Code of Ethics: Core Principles, Boundaries, and Dual Relationships 13.2 Cultural Humility, Implicit Bias, and Culturally Responsive Care 13.3 Clinical Supervision, Professional Impairment, Compassion Fatigue, and Self-Care 13.4 Technology in Practice: Telehealth, E-Supervision, AI, and Social Media 13.5 Professional Development, Credentialing, and Scope of Practice

5.1 Medical Evaluation, Toxicology Screening, and Infectious Disease Risks

Key Takeaways Explain This Topic AI

Toxicology screening relies on a two-tier model: initial immunoassay (rapid, presumptive, susceptible to cross-reactivity) followed by confirmatory Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for definitive molecular identification.

Specimen Validity Testing (SVT) evaluates temperature (90.0°F–100.0°F within 4 minutes), specific gravity (1.002–1.030), creatinine (≥20 mg/dL), pH (4.5–8.9), and exogenous oxidants/adulterants to detect diluted, substituted, or adulterated specimens.

Substance detection windows vary by matrix, dose, and lipophilicity; standard urine immunoassay detects cocaine (2–4 days), opioids (1–3 days), amphetamines (1–3 days), and single-use cannabis (1–3 days), while chronic heavy cannabis use can persist for 30–45+ days in adipose stores.

Addiction counselors must screen for common infectious co-morbidities including HIV/AIDS, Hepatitis B (HBV), Hepatitis C (HCV), STIs, and Tuberculosis (TB), implementing Universal Precautions, CDC opt-out testing, and harm reduction modalities (e.g., Syringe Services Programs, Naloxone).

Severe sedative-hypnotic and alcohol withdrawal syndromes (Delirium Tremens, withdrawal seizures) are medical emergencies requiring immediate pharmacological stabilization with benzodiazepines and parenteral thiamine prior to dextrose administration to prevent Wernicke-Korsakoff encephalopathy.

Last updated: August 2026

Medical Evaluation, Toxicology Screening, and Infectious Disease Risks

Comprehensive addiction treatment requires a robust integration of clinical counseling skills with biomedical evaluation. Substance use disorders (SUDs) induce profound physiological adaptations, severe end-organ damage, heightened vulnerability to infectious diseases, and potentially fatal withdrawal syndromes. Addiction professionals must understand the medical assessment process, master the clinical interpretation of toxicology testing, recognize the parameters of specimen validity, identify false positives, and coordinate emergency medical interventions for high-risk withdrawal and infectious conditions.

1. Medical Assessment in Addiction Treatment

Under SAMHSA Guidelines and the ASAM Criteria (Dimension 1: Acute Intoxication and/or Withdrawal Potential; Dimension 2: Biomedical Conditions and Complications) , every individual entering substance use disorder treatment must undergo medical screening and, where indicated, a comprehensive biomedical evaluation conducted by qualified medical personnel (physician, physician assistant, or advanced practice registered nurse). +-----------------------------------------------------------------------------+

  • | BIOMEDICAL EVALUATION IN ADDICTION CARE |
  • | |
  • | [PHYSICAL EXAMINATION] --> Vital signs, cardiovascular, pulmonary, |
  • | dermatological, neurological, dental systems |
  • | | |
  • | [LABORATORY WORKUP] --> Complete Blood Count (CBC), Metabolic Panel, |
  • | Liver Function (LFTs), Renal, Coagulation |
  • | | |
  • | [INFECTIOUS SCREENING] --> HIV Ag/Ab, HCV Ab w/ RNA Reflex, HBV Serology,|
  • | RPR/VDRL (Syphilis), NAAT (GC/CT), TB / IGRA |
  • | | |
  • | [TOXICOLOGY SCREENING] --> Specimen Validity + Immunoassay Screen |
  • | + Confirmatory GC-MS / LC-MS/MS if Indicated |
  • +-----------------------------------------------------------------------------+

Clinical Components of the Baseline Medical Assessment:

Vital Signs & Hemodynamic Stability: Resting pulse, blood pressure, respiratory rate, and body temperature. Tachycardia (>100 bpm), severe hypertension (systolic >160 mmHg or diastolic >100 mmHg), and pyrexia signal acute intoxication, severe withdrawal, or systemic infection (e.g., infective endocarditis or sepsis).

Dermatological Examination: Identifying track marks, cutaneous scarring, skin popping lesions, venous sclerosis, cellulitis, subcutaneous abscesses, jaundice (icterus), spider angiomas, and palmar erythema.

Cardiovascular & Pulmonary Assessment: Auscultation for new cardiac murmurs (indicative of right- or left-sided infective endocarditis secondary to injection drug use), arrhythmias, pulmonary wheezing, crackles, or signs of aspiration pneumonia and chronic obstructive pulmonary disease (COPD).

Neurological Examination: Evaluating level of consciousness, orientation, cranial nerves, pupil size and reactivity (pinpoint in opioid toxicity; dilated in stimulant/opioid withdrawal or anticholinergic toxicity), gross tremors, nystagmus, cerebellar ataxia, deep tendon reflexes, and peripheral neuropathy (common in chronic alcoholism and thiamine deficiency).

Gastrointestinal & Hepatic Assessment: Palpation for hepatomegaly, splenomegaly, abdominal tenderness, ascites, and screening for upper gastrointestinal bleeding (hematemesis, melena) secondary to esophageal varices or peptic ulcer disease.

Baseline Laboratory Biomarkers in SUD:

Complete Blood Count (CBC): Evaluates for anemia, leukocytosis (infection/abscess), thrombocytopenia (hypersplenism from portal hypertension), and Mean Corpuscular Volume (MCV) . An elevated MCV (>100 fL, macrocytosis) serves as a classic long-term objective biomarker of chronic heavy alcohol consumption.

Liver Function Tests (LFTs):

Aspartate Aminotransferase (AST) & Alanine Aminotransferase (ALT): Elevated in acute toxic, ischemic, or viral hepatitis. An AST-to-ALT ratio greater than 2:1 (De Ritis ratio) strongly suggests alcoholic liver disease.

Gamma-Glutamyl Transferase (GGT): A highly sensitive microsomal enzyme induced by chronic alcohol ingestion; elevated GGT with normal alkaline phosphatase points toward heavy alcohol use.

Albumin & Total Bilirubin / Prothrombin Time (PT/INR): True markers of hepatic synthetic capacity. Hypoalbuminemia and prolonged INR signal advanced cirrhosis or liver failure.

Renal Function & Electrolytes: Blood Urea Nitrogen (BUN), serum creatinine, and estimated Glomerular Filtration Rate (eGFR) to detect dehydration, acute kidney injury (e.g., secondary to rhabdomyolysis from prolonged stimulant/sedative immobility), and electrolyte derangements (hypokalemia, hypomagnesemia, hypophosphatemia).

2. Toxicology Screening Methodologies: Immunoassay vs. Confirmatory GC-MS / LC-MS

Toxicology drug screening is a critical clinical tool utilized to monitor treatment adherence, establish baseline substance exposure, verify abstinence, and ensure safety in medication management. Toxicology testing is governed by a two-tier testing paradigm : +-----------------------------------------------------------------------------+

  • | THE TWO-TIER TOXICOLOGY PARADIGM |
  • | |
  • | TIER 1: SCREENING IMMUNOASSAY (EIA / ELISA / CEDIA / Lateral Flow) |
  • | • Rapid, high-throughput, low cost |
  • | • Class-specific antibodies bind target drug or metabolites |
  • | • High Sensitivity / Moderate Specificity |
  • | • RESULT: PRESUMPTIVE POSITIVE or NEGATIVE |
  • | | |
  • | v (If Contested or Requiring Definitive Proof) |
  • | TIER 2: CONFIRMATORY TESTING (GC-MS or LC-MS/MS) |
  • | • Chromatographic separation + Mass spectral fragmentation fingerprinting |
  • | • Compound-specific molecular identification & precise quantitation |
  • | • Virtually 100% Specificity (Eliminates Cross-Reactivity) |
  • | • RESULT: DEFINITIVE CONFIRMATORY POSITIVE or NEGATIVE |
  • +-----------------------------------------------------------------------------+
  • Comparison Table: Immunoassay vs. GC-MS / LC-MS

Feature / Dimension Immunoassay (Presumptive Screen) GC-MS / LC-MS/MS (Confirmatory Gold Standard)

Analytical Principle Antigen-antibody competitive binding reaction. Physical chromatographic separation followed by mass-to-charge ratio ( m / z m/z m / z ) spectral fragmentation.

Diagnostic Classification Presumptive (Preliminary qualitative or semi-quantitative). Definitive (Confirmatory qualitative and quantitative).

Turnaround Time Immediate (point-of-care cups: 5–10 min; lab analyzer: 1–4 hours). 24 to 72 hours (requires complex instrument preparation and analytical run).

Relative Cost Inexpensive ($5–$25 per panel). Moderate to High ($50–$200+ per specimen).

Sensitivity & Specificity High sensitivity (low false-negative rate); Moderate specificity. High sensitivity and near-perfect specificity (100%) ; eliminates false positives.

Cross-Reactivity Risk High ; structurally related over-the-counter and prescription drugs cross-react. Zero cross-reactivity; identifies exact unique molecular structural fingerprints.

Compound Differentiation Cannot differentiate specific drugs within a class (e.g., cannot distinguish morphine from codeine). Precisely differentiates parent drugs, synthetic variants, and specific metabolites (e.g., 6-MAM vs. codeine).

Clinical / Legal Role Rapid clinical triage and initial monitoring. Punitive or legal action on presumptive results alone is clinically and legally unethical. Legally defensible standard in forensic, workplace, child welfare, and contested clinical settings.

Important

Clinical Best Practice Rule: An immunoassay drug screen result is strictly presumptive . Whenever a client denies using a substance that yielded a positive immunoassay, or when significant clinical, legal, or child welfare consequences hinge upon the result, the addiction counselor must never impose punitive sanctions based solely on the immunoassay. The specimen must be reflexed to laboratory GC-MS or LC-MS/MS confirmatory testing .

3. Windows of Detection, Cutoff Thresholds, and Metabolism

The detection window of a substance is governed by route of administration, dosage, frequency of use (acute vs. chronic), metabolic rate, renal/hepatic clearance, and the chemical lipophilicity of the drug and its metabolites.

Comprehensive Substance Detection Windows and Cutoffs Table

Substance & Target Analytes Specimen Matrix Initial Immunoassay Cutoff Confirmatory Cutoff (GC-MS / LC-MS) Typical Window of Detection Metabolic & Pharmacokinetic Notes

Alcohol (Ethanol) ; • Parent Ethanol Breath / Blood / Urine 0.02–0.08 g/dL (Blood/Breath); 10–20 mg/dL (Urine) Gas Chromatography: 10 mg/dL Blood/Breath: 6–12 hours; Urine: 10–24 hours Metabolized at ~0.015–0.020 g/dL/hour via alcohol dehydrogenase and CYP2E1. Rapidly cleared.

Alcohol Biomarkers ; • Ethyl Glucuronide (EtG); • Ethyl Sulfate (EtS) Urine 500 ng/mL (Clinical); 100 ng/mL (Forensic) LC-MS/MS:; 100–250 ng/mL (EtG); 50–100 ng/mL (EtS) EtG/EtS: 24 to 80 hours (up to 3–5 days after heavy binge consumption) Direct non-oxidative minor phase II metabolites. Highly stable in urine; sensitive to heavy recent drinking.

Alcohol Biomarker ; • Phosphatidylethanol (PEth) Whole Blood (Dried Blood Spot) N/A (Direct LC-MS) LC-MS/MS:; ≥20 ng/mL (Moderate); ≥200 ng/mL (Heavy) PEth: 2 to 4 weeks (half-life ~4–10 days) Formed exclusively in erythrocyte membranes in the presence of ethanol. Zero false positives from incidental alcohol exposure.

Amphetamines ; • d/l-Amphetamine; • d/l-Methamphetamine Urine 500 ng/mL (SAMHSA); 300 ng/mL (Clinical) 250 ng/mL (GC-MS/LC-MS) 1 to 3 days (up to 4–5 days in heavy, chronic use) Renal excretion is highly pH-dependent: acidic urine accelerates clearance; alkaline urine prolongs excretion.

Benzodiazepines ; • Oxazepam / Nordiazepam; • Lorazepam / Clonazepam Urine 200–300 ng/mL 100–200 ng/mL (LC-MS/MS) Short-acting: 1–3 days (alprazolam, lorazepam); Long-acting: 7 to 30 days (diazepam, chlordiazepoxide) Lipophilic; long-acting agents yield active metabolites with prolonged elimination half-lives. Lorazepam and clonazepam frequently cause false-negative immunoassays.

Cannabinoids (THC) ; • 11-nor-9-carboxy-THC (THC-COOH) Urine 50 ng/mL (SAMHSA) 15 ng/mL (GC-MS/LC-MS) Single use: 1–3 days; Moderate (3x/wk): 5–7 days; Daily chronic: 10–15 days; Heavy chronic / obese: 30 to 45+ days Highly lipophilic; accumulates in adipose tissue and leaches slowly into blood and urine over extended periods of abstinence.

Cocaine ; • Benzoylecgonine (BE) Urine 150–300 ng/mL 100 ng/mL (GC-MS/LC-MS) Acute use: 2 to 4 days; Chronic heavy use: 10 to 14 days Cocaine is rapidly hydrolyzed to benzoylecgonine. Co-ingestion with alcohol produces cocaethylene , which possesses an extended half-life and heightened cardiotoxicity.

Opiates (Natural) ; • Morphine, Codeine; • 6-Monoacetylmorphine Urine 2,000 ng/mL (SAMHSA); 300 ng/mL (Clinical) 2,000 / 300 ng/mL; 6-MAM: 10 ng/mL Morphine/Codeine: 1–3 days; 6-MAM: 8 to 24 hours 6-MAM is unique to heroin and confirms heroin use without cross-reactivity to poppy seeds or codeine.

Semi-Synthetic Opioids ; • Oxycodone, Oxymorphone Urine 100–300 ng/mL (Targeted screen) 100 ng/mL (GC-MS/LC-MS) 1 to 3 days Standard opiate immunoassays miss oxycodone/oxymorphone ; dedicated oxycodone reagent is required.

Synthetic Opioids ; • Fentanyl & Norfentanyl; • Methadone & EDDP; • Buprenorphine Urine Fentanyl: 1–2 ng/mL; Methadone: 300 ng/mL; Buprenorphine: 5–10 ng/mL Fentanyl: 0.5–1.0 ng/mL; EDDP: 100 ng/mL; Buprenorphine: 5 ng/mL Fentanyl: 1–4 days (up to 7+ days chronic); Methadone: 3–5 days; Buprenorphine: 3–7 days Standard opiate screen does NOT detect fentanyl, methadone, or buprenorphine. Dedicated assays are mandatory.

Phencyclidine (PCP) Urine 25 ng/mL 25 ng/mL 3 to 7 days (up to 14–30 days in chronic, heavy users) Highly lipophilic and stored in adipose and brain tissue; re-enters circulation during lipolysis.

4. Cross-Reactivity, False Positives, and Specimen Validity Testing (SVT)

Common Immunoassay Cross-Reactions (False Positives):

Opiates: Ingestion of food products containing poppy seeds (which contain natural morphine/codeine; federal guidelines raised screening cutoffs from 300 ng/mL to 2,000 ng/mL to prevent dietary false positives); Quinolone antibiotics (levofloxacin, ciprofloxacin); Rifampin .

Amphetamines / Methamphetamine: Pseudoephedrine and ephedrine (nasal decongestants); Bupropion (Wellbutrin) ; Labetalol (antihypertensive); Ranitidine ; Phentermine ; Vicks Inhaler (l-methamphetamine) .

Benzodiazepines: Sertraline (Zoloft) ; Oxaprozin (Daypro) ; Efavirenz (HIV NNRTI).

Cannabinoids (THC): Pantoprazole (Proton pump inhibitor); Efavirenz ; NSAIDs (historical assays).

Phencyclidine (PCP): Dextromethorphan (DXM) (cough suppressants); Venlafaxine (Effexor) ; Diphenhydramine (Benadryl) ; Tramadol ; Lamotrigine .

EtG (Alcohol): Incidental exposure to ethanol-based hand sanitizers, mouthwash, baked goods made with pure vanilla extract, or fermented foods. Clinical guidelines recommend an EtG cutoff of 500 ng/mL to prevent false accusations from environmental/incidental contact.

Specimen Validity Testing (SVT) Standards:

To ensure that urine specimens have not been tampered with, adulterated, diluted, or substituted, laboratories and clinics perform mandatory Specimen Validity Testing (SVT) . +-----------------------------------------------------------------------------+

  • | SPECIMEN VALIDITY TESTING METRICS |
  • | |
  • | [TEMPERATURE] --> 90.0°F to 100.0°F (32.2°C to 37.8°C) within 4 min |
  • | |
  • | [SPECIFIC GRAVITY] --> Normal: 1.002 to 1.030 |
  • | Dilute: < 1.003 (with Creatinine < 20 mg/dL) |
  • | |
  • | [CREATININE] --> Normal: >= 20.0 mg/dL |
  • | Dilute: 2.0 to < 20.0 mg/dL |
  • | Substituted: < 2.0 mg/dL (Not Human Urine) |
  • | |
  • | [pH] --> Normal: 4.5 to 8.9 |
  • | Adulterated: < 3.0 or >= 11.0 |
  • | |
  • | [OXIDANTS] --> Bleach, Pyridinium chlorochromate (PCC), Nitrites, |
  • | Glutaraldehyde = ADULTERATED SPECIMEN |
  • +-----------------------------------------------------------------------------+

Clinical Classifications of Specimen Validity:

Valid Specimen: Temperature 90.0°F–100.0°F, Creatinine ≥20.0 mg/dL, Specific Gravity 1.002–1.030, pH 4.5–8.9, negative for chemical oxidants.

Dilute Specimen: Creatinine is between 2.0 and <20.0 mg/dL AND Specific Gravity is <1.003 . May result from intentional water loading (flushing) or excessive healthy hydration.

Clinical Action: If the drug screen is Positive Dilute , it is treated as a positive result. If it is Negative Dilute , the counselor should require an immediate recollection with fluid restriction.

Substituted Specimen: Creatinine is <2.0 mg/dL AND Specific Gravity is ≤1.001 or ≥1.020 . These values are physiologically impossible for human urine, indicating the specimen is synthetic urine, apple juice, water, or other liquids.

Adulterated Specimen: Contains exogenous chemical agents (e.g., bleach, soap, vinegar, pyridinium chlorochromate [PCC], glutaraldehyde, nitrites >500 mcg/mL) or has a pH <3.0 or ≥11.0 .

5. Infectious Disease Risks in Addiction Treatment

Individuals with substance use disorders exhibit disproportionately high rates of bloodborne, sexually transmitted, and airborne infectious diseases resulting from high-risk injection practices (sharing needles, cookers, cotton, rinse water) and high-risk sexual behaviors under the influence of disinhibiting substances (e.g., stimulants, alcohol).

Infectious Disease Risk, Screening, and Management Table

Condition & Pathogen Primary Transmission & SUD Risk Factors Standard Screening & Diagnostic Protocol Clinical Management & Counselor Role Harm Reduction & Prevention Modalities

HIV / AIDS ; (Human Immunodeficiency Virus) • Sharing syringes, needles, paraphernalia.; • Unprotected condomless sexual encounters.; • Stimulant-associated "chemsex." 4th-Generation HIV-1/2 Ag/Ab Immunoassay (detects p24 antigen and antibodies). Positive screen reflexes to quantitative HIV-1 RNA PCR Viral Load . Linkage to rapid Antiretroviral Therapy (ART) ; adherence counseling. Educate on U=U (Undetectable = Untransmittable) : viral load <200 copies/mL prevents sexual transmission. • PrEP (Pre-Exposure Prophylaxis): Daily emtricitabine/tenofovir or long-acting cabotegravir.; • PEP (Post-Exposure): Within 72 hours of exposure.; • Syringe Services Programs (SSPs).

Hepatitis C (HCV) ; (Hepatitis C Virus) • Most prevalent bloodborne infection in PWID (~60–80% prevalence).; • Highly infectious; survives in dried blood/syringes for weeks. HCV Antibody Screen reflexed to Quantitative HCV RNA PCR . (Antibody confirms lifetime exposure; RNA confirms active, replicating viremic infection). Directly Acting Antivirals ( DAAs , e.g., sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) provide >95% cure rates in 8–12 weeks . Abstinence from alcohol to prevent rapid cirrhosis. • Sterile injection equipment distribution.; • Never share cookers, cotton, or rinse water.; • Annual HCV RNA screening for active PWID.

Hepatitis B (HBV) ; (Hepatitis B Virus) • Bloodborne and sexual transmission.; • Perinatal transmission.; • Highly stable and transmissible virus. Hepatitis B Serologic Panel: ; • HBsAg: Active infection.; • Anti-HBs: Immunity (vaccine or natural).; • Anti-HBc: Past or current natural infection. Linkage to infectious disease/hepatology for antiviral management (e.g., tenofovir, entecavir) if chronic infection is confirmed. • HBV Vaccination: 3-dose series (or 2-dose Heplisav-B) recommended for all SUD clients.; • Universal precautions and barrier protection.

Sexually Transmitted Infections (STIs) ; • Syphilis ( T. pallidum ); • Gonorrhea ( N. gonorrhoeae ); • Chlamydia ( C. trachomatis ) • Unprotected sexual activity.; • Transactional sex for drugs or shelter.; • Severe stimulant binge use. • Syphilis: RPR or VDRL screen with reflex FTA-ABS / TP-PA treponemal confirmation.; • GC/CT: NAAT (Nucleic Acid Amplification Test) of urine, pharyngeal, or rectal swabs. Linkage for antibiotic therapy (Benzathine Penicillin G for syphilis; Ceftriaxone + Doxycycline for GC/CT). Partner notification and expedited partner therapy. • Free condom distribution.; • Routine, opt-out STI screening at intake.; • Trauma-informed sexual health education.

Tuberculosis (TB) ; (Mycobacterium tuberculosis) • Airborne droplet nuclei .; • Crowded congregate living (shelters, detox units, correctional facilities).; • Immunocompromise (HIV co-infection). Tuberculin Skin Test (TST / PPD Mantoux) read at 48–72 hours (≥10 mm induration is positive in PWID/congregate settings; ≥5 mm in HIV). OR IGRA Blood Test (QuantiFERON-TB Gold) . Positive Screen: Mandatory Chest X-ray and sputum AFB smear/culture to rule out active pulmonary TB before admission to congregate SUD treatment. • Immediate Airborne Infection Isolation (negative-pressure room) for suspected active TB.; • Rifampin/Isoniazid latent TB therapy.

6. Universal Precautions and Harm Reduction Principles

Addiction counselors and treatment facilities must adhere to CDC Standard Precautions (Universal Precautions) , operating under the clinical assumption that all human blood, bodily fluids, and tissues are potentially infectious. +-----------------------------------------------------------------------------+

  • | STANDARD PRECAUTIONS & HARM REDUCTION |
  • | |
  • | UNIVERSAL PRECAUTIONS: |
  • | • Routine hand hygiene (soap/water or alcohol rub) |
  • | • Personal Protective Equipment (PPE: gloves for specimen collection) |
  • | • Puncture-resistant sharps biohazard disposal (NEVER recap needles) |
  • | • Environmental disinfection: 1:10 sodium hypochlorite (bleach) solution |
  • | |
  • | EVIDENCE-BASED HARM REDUCTION: |
  • | • Syringe Services Programs (SSPs): Sterile needles, cookers, sterile H2O |
  • | • Naloxone (Narcan) Distribution & Opioid Overdose Education |
  • | • Fentanyl & Xylazine Test Strips |
  • | • Overdose Prevention Centers (OPCs) / Supervised Consumption Services |
  • +-----------------------------------------------------------------------------+

Note

Harm Reduction Science: Decades of epidemiological research demonstrate that Syringe Services Programs (SSPs) do not increase drug use or crime. SSP participants are 5 times more likely to enter addiction treatment and experience a ~50% reduction in HIV and HCV incidence compared to non-participants.

7. Managing Life-Threatening Withdrawal Syndromes

While opioid and stimulant withdrawal produce profound psychological distress and intense flu-like symptoms, they are rarely fatal in healthy individuals. In contrast, Alcohol Withdrawal Syndrome (AWS) and Benzodiazepine Withdrawal can be directly life-threatening emergencies requiring immediate medical hospitalization and pharmacological detoxification. +-----------------------------------------------------------------------------+

  • | ALCOHOL WITHDRAWAL SEVERITY TIMELINE |
  • | |
  • | [6 - 12 HOURS] --> Autonomic Hyperactivity (Tremors, sweating, nausea, |
  • | tachycardia, hypertension, insomnia, agitation) |
  • | |
  • | [12 - 48 HOURS] --> Alcoholic Hallucinosis (Visual, tactile, or auditory |
  • | perceptual disturbances; INTACT SENSORIUM / ORIENTED) |
  • | |
  • | [24 - 48 HOURS] --> Withdrawal Seizures (Generalized tonic-clonic; |
  • | high risk of progression to status epilepticus) |
  • | |
  • | [48 - 96 HOURS] --> DELIRIUM TREMENS (DTs) (Profound delirium, confusion, |
  • | hallucinations, malignant hyperthermia, autonomic |
  • | collapse; 5-15% MORTALITY IF UNTREATED) |
  • +-----------------------------------------------------------------------------+

Clinical Management of Alcohol and Benzodiazepine Withdrawal:

CIWA-Ar Monitoring: The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is a 10-item validated instrument scored from 0 to 67 . Scores ≥10 to 15 indicate moderate withdrawal requiring pharmacological intervention; scores ≥20 indicate severe, high-risk withdrawal requiring intensive medical monitoring.

Benzodiazepine Pharmacotherapy: Benzodiazepines act as cross-tolerant GABA-A receptor agonists, preventing seizures and suppressing autonomic hyperactivity:

Long-Acting Agents (Diazepam, Chlordiazepoxide): Preferred in clients with normal hepatic function due to smooth, self-tapering pharmacokinetics.

Short/Intermediate-Acting Agents (Lorazepam, Oxazepam - "LOT" drugs): Mandatory for clients with hepatic cirrhosis, liver failure, or older adults because they undergo direct glucuronidation without Phase I hepatic oxidation, preventing drug accumulation and hepatic encephalopathy.

Thiamine (Vitamin B1) Administration (Wernicke-Korsakoff Prevention):

Chronic alcoholism induces severe thiamine deficiency via malabsorption and poor dietary intake.

Critical Clinical Rule: Administer parenteral Thiamine (100–500 mg IV/IM) BEFORE any intravenous dextrose (glucose) infusion .

Rationale: Glucose metabolism consumes thiamine. Infusing glucose without prior thiamine supplementation precipitates acute Wernicke's Encephalopathy (triad: confusion/encephalopathy, oculomotor dysfunction/nystagmus, ataxia), which can progress irreversibly to Korsakoff's Psychosis (anterograde/retrograde amnesia, confabulation).

Benzodiazepine Tapering Protocol: Abrupt cessation of chronic benzodiazepines is contraindicated. Management requires a gradual, structured dose reduction over weeks to months, often converting short-acting agents (alprazolam, lorazepam) to an equivalent dose of a long-acting agent (diazepam, clonazepam).

Loading diagram... Toxicology Screening and Confirmatory Decision Workflow